Efficacy of Cannabis Oil for Alleviating Side Effects of Breast Cancer Chemotherapy: A Randomized Double-blinded Controlled Trial

Thai Traditional Medical Knowledge Fund0 个研究点目标入组 90 人开始时间: 2022年8月9日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Women aged 18-70 years old who were diagnosed with breast cancer; 2. Metastatic breast cancer patients who are currently receiving different doses of chemotherapy
•regimen with high/low emetic risk such as AC (cyclophosphamide and doxorubicin), AC followed by T (cyclophosphamide, doxorubicin, and paclitaxel), DC (cyclophosphamide and docetaxel), CMF (cyclophosphamide, fluorouracil, and methotrexate), and Paclitaxel; 3. Breast cancer patients at King Chulalongkorn Memorial Hospital (KCMH) from November 2022 to March 2023; 4. Participants provided written informed consent, 5. Individual has at least ESAS score more than and equal to 3.

•1. Women who have contraindications for chemotherapy such as anaphylaxis, 2. Women who have serious chemotherapy complications such as anaphylactic shock, bone marrow suppression, liver failure, acute kidney injury, and cardiac arrest, 3. Women who are scheduled elective surgery or other procedures requiring general anesthesia during the study, 4. Women who are in pregnant or lactating, and who are planned for pregnancy during the study, 5. Women who are terminally ill or inappropriate for placebo medication, 6. Women with any other significant disease or disorder which, in the opinion of the investigator, may have put the patient at risk because of participation in the study, or may have influence the result of the study, or the patients' ability to participate in the study, 7. Women with known history of substance abuse, 8. Women with history of cannabis ingredients allergy or suspected of having adverse reaction to cannabis, 9. Women using antibiotics within the past 3 months or using NSAIDs drugs, 10. Women consuming probiotic or prebiotic supplements.

发起方

Thai Traditional Medical Knowledge Fund